bioRxivCell BiologyPreprint
TNFα-driven Aβ aggregation, synaptic dysfunction and hypermetabolism in human iPSC-derived cortical neurons
Alicia González DíaziD, Elisa Belli, Benedetta ManniniiD, Gustavo Antonio Urrutia, Michele VendruscoloiD
Abstract
Alzheimers disease (AD) patients exhibit an increased load of A{beta} aggregates in the brain parenchyma. The neurotoxic nature of these aggregates has been underscored by recent advances in therapies aimed at reducing their load. To make further progress towards the development of increasingly effective treatments, there is a still largely unmet need for reliable cell models that comprehensively recapitulate aggregate-driven AD pathology. Here, we report a robust and scalable pipeline for generating human iPSC-derived cortical neurons that display A{beta} aggregates in their axonal projections. This phenotype is caused by a repeated dosage of tumour necrosis factor-alpha (TNF) to simulate the chronic inflammatory environment characteristic of AD and enhanced in neurons carrying the Swedish mutation. In association with the increased A{beta} deposits in the cell bodies, this cell model exhibits other key hallmarks of AD, including structural alterations of synapses, electrophysiological asynchronous hyperactivity, and hypermetabolism. Overall, these results illustrate how repeated TNF treatment models central aspects of AD pathology, and provides a platform that could be used for facilitating the translation of potential drugs to clinical applications.
- organism: human
- assay: proteomics
- assay: electrophysiology
- assay: metabolomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Tau depletion in human neurons mitigates A beta-driven toxicity
Bryan Ng, Jane Vowles, … Richard Wade‐Martins·Molecular PsychiatryPeer-reviewed·Feb 15, 2024
- Comprehensive characterization of the neurogenic and neuroprotective action of a novel TrkB agonist using mouse and human stem cell models of Alzheimer's Disease
D. Charou, T. Rogdakis, … I. Charalampopoulos·bioRxiv·May 8, 2023
- A human neuronal model of sporadic Alzheimer's disease induced by FBXO2 downregulation shows A β aggregation, tau hyperphosphorylation and functional network impairment
Alicia González Díaz, Andrea Possenti, … Michele Vendruscolo·bioRxiv·Sep 1, 2024
- A scalable human neuron model of Alzheimer's disease relevant tauopathy reveals mechanisms linking Tau fibrillization to synaptic dysfunction
Joanna Lipka, Xiwei Shan, … Jasvinder K. Atwal·bioRxiv·Sep 12, 2026
- 3D bioengineered neural tissue generated from patient-derived iPSCs develops time-dependent phenotypes and transcriptional features of Alzheimer's disease
Selene Lomoio, Ravi S. Pandey, … Giuseppina Tesco·Molecular PsychiatryPeer-reviewed·Jun 26, 2023
- Autophagy activators normalize aberrant Tau proteostasis and rescue synapses in human familial Alzheimer's disease iPSC-derived cortical organoids
Sergio R. Labra, Jadon Compher, … Stuart A. Lipton·Advanced SciencePeer-reviewed·Jan 27, 2026